Cantor Fitzgerald Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $200.00

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective hoisted by research analysts at Cantor Fitzgerald from $170.00 to $200.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 31.05% from the company’s previous close.

Several other research firms have also recently weighed in on ASND. Oppenheimer reduced their price objective on Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research note on Thursday, February 13th. Evercore ISI increased their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, February 18th. Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $202.36.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $152.61 on Tuesday. The business’s 50-day simple moving average is $135.40 and its 200-day simple moving average is $133.67. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $158.06. The stock has a market capitalization of $9.26 billion, a PE ratio of -21.49 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.32) by $0.64. On average, research analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Signaturefd LLC boosted its position in shares of Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 80 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Ascendis Pharma A/S by 63.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after buying an additional 4,338 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in Ascendis Pharma A/S by 5.9% during the 3rd quarter. Rice Hall James & Associates LLC now owns 160,614 shares of the biotechnology company’s stock worth $23,981,000 after acquiring an additional 8,958 shares during the period. Pursue Wealth Partners LLC acquired a new position in Ascendis Pharma A/S in the 3rd quarter valued at $217,000. Finally, Harbor Capital Advisors Inc. lifted its position in shares of Ascendis Pharma A/S by 67.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 87,302 shares of the biotechnology company’s stock valued at $13,035,000 after acquiring an additional 35,102 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.